Nuvation Bio Inc reports results for the quarter ended June 30 - Earnings Summary

• Nuvation Bio Inc NUVB.N reported a quarterly adjusted loss of 17 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -15 cents. The mean expectation of seven analysts for the quarter was for a loss of 17 cents per share. Wall Street expected results to range from -19 cents to -15 cents per share.

• Revenue rose 236.8% to $4.83 million from a year ago; analysts expected $357.14 thousand.

• Nuvation Bio Inc's reported EPS for the quarter was a loss of 17 cents​.

• The company reported a quarterly loss of $59.01 million.

• Nuvation Bio Inc shares had risen by 20.5% this quarter and lost 11.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Nuvation Bio Inc is $6.00, about 60.8% above its last closing price of $2.35

This summary was machine generated from LSEG data August 7 at 05:27 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)